Test drug injected directly into tumors for advanced cancers
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests OH2 given as an injection directly into certain tumors (intratumoral injection) in people with advanced melanoma or several other solid cancers that are hard to remove. It aims to see whether the treatment is safe and if it can help control cancer by reaching the tumor more directly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older
- You have confirmed advanced (unresectable or metastatic) melanoma or specific solid tumors, and your cancer has measurable spots that can be injected
- At least one tumor spot is in the right place and size (about 10–60 mm) for direct injection
- Your cancer has either grown after standard treatment or you can’t get standard treatment, and enough time has passed since your last therapy
- You must be well enough for study visits (life expectancy of at least 12 weeks, and ECOG 0–1)
- You must follow birth control rules (if applicable) and agree not to join another drug study at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a virus therapy designed to attack solid tumors that cannot be removed by surgery or have returned/spread. It may help shrink tumors and control cancer in people whose standard treatments are no longer working.
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
This trial tests an investigational cell therapy called HS-IT201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if this treatment can help shrink tumors or slow their growth.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
This Phase 3 study tests OH2 injection in people with stage III or IV melanoma that has come back or spread after at least two prior treatment types. If you qualify, you may receive OH2 injection to help shrink tumors or slow disease progression.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.